Why the study?
The mechanism of atrial fibrillation has not been fully elucidated, and existing approaches to its diagnosis and treatment face limitations.
This review highlights the potential of exosomes as novel biomarkers and therapeutic targets in atrial fibrillation.
Answers are grounded in this paper and cite their sources.
Exosomes may support AF biomarker and therapeutic development; hypothesis-generating review that leaves clinical translation open.
Atrial fibrillation (AF) is the most common persistent arrhythmia, but the mechanism of AF has not been fully elucidated, and existing approaches to diagnosis and treatment face limitations. Recently, exosomes have attracted considerable interest in AF research due to their high stability, specificity and cell-targeting ability. The aim of this review is to summarize recent literature, analyze the advantages and limitations of exosomes, and to provide new ideas for their use in understanding the mechanism and improving the diagnosis and treatment of AF.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: